At 6 months follow-up, 15% of topiramate patients and 11% of lamotrigine patients were found to be satisfied.32% of topiramate and 38% of lamotrigine patients experienced 50% seizure reduction. 8% of topiramate and 3% of lamotrigine subjects experienced adverse reactions (e.g. cognitive effects, mood, behavioural, etc.). Furthermore, 6% of topiramate patients were seizure-free compared with 15% of lamotrigine subjects. On average, 64% were still receiving the prescribed adjunctive drug at 6 months.